Answers are grounded in this paper and cite their sources.
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a serious threat to global public health, and is imposing severe burdens on human society. Several candidate vaccines against SARS-CoV-2 are now undergoing clinical trials. The Spike (S) protein of SARS-CoV-2 is widely considered as a promising antigen. However, limited information about the protective immune response against SARS-CoV-2 has been reported. 1 In vivo or in natura data of the immune response in patients, including major immune responses to S protein, are currently lacking. The development of effective and safe vaccines against SARS-CoV-2 is urgently needed because of some potential adverse events including antibody-dependent enhancement (ADE), 2 which might be difficult to avoid in current vaccine designs. Therefore, it is important to mine serological information from COVID-19 patients. In this study, we analysed the correlation between S- or Nucleocapsid (N) protein-specific antibody levels and neutralizing antibody tires. Furthermore, we aimed to identify linear B cell linear immunodominant (ID) sites on the S protein by Pepscan analysis with a series of overlapped peptides against the sera from COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: